C20orf95 Inhibitors
C20orf95 Inhibitors refer to a specific category of chemical compounds engineered to selectively impede the activity of the C20orf95 protein. The designation C20orf95 stands for Chromosome 20 Open Reading Frame 95, denoting a gene that encodes a protein whose functional intricacies remain largely undiscovered. As researchers explore the vast landscape of the human genome, proteins like C20orf95 have captured attention due to their enigmatic nature and potential roles in cellular processes. In the realm of scientific inquiry, the development of inhibitors targeting C20orf95 assumes significance, offering a method to dissect the molecular pathways and functions associated with this protein.
The meticulous design of C20orf95 inhibitors involves an in-depth understanding of the protein's structure and its interactions within cellular contexts. These inhibitors are crafted with a high degree of specificity, aiming to selectively bind to key regions of C20orf95 and disrupt its normal biochemical functions. By leveraging these inhibitory compounds as research tools, scientists can probe the cellular consequences of interfering with C20orf95, shedding light on its potential roles in cellular homeostasis or signaling pathways. The development and study of C20orf95 inhibitors contribute to the broader scientific endeavor of unraveling the complexities of the human proteome, fostering a deeper understanding of the functions and implications of less-explored genes and proteins in cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase, potentially impacting prenylation of Rho GTPases, thereby downregulating ARHGAP40 expression linked to Rho GTPase regulation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective Rho-associated protein kinase (ROCK) inhibitor. By blocking ROCK activity, it may indirectly affect ARHGAP40 expression, given its role in modulating Rho GTPase signaling pathways. | ||||||
Fluoxetine hydrochloride | 56296-78-7 | sc-201125 sc-201125A sc-201125B sc-201125C | 50 mg 250 mg 1 g 5 g | $77.00 $213.00 $407.00 $849.00 | 14 | |
Secramine A interferes with Cdc42, a member of the Rho GTPase family. By disrupting Cdc42 activity, it may indirectly affect ARHGAP40 expression as part of the intricate Rho GTPase regulatory network. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $135.00 | 19 | |
IWR-1-endo is a Wnt pathway inhibitor that may influence downstream signaling cascades, potentially impacting ARHGAP40 expression linked to Wnt-dependent regulation of Rho GTPase pathways. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
Rhosin is a selective inhibitor of RhoA activation. By inhibiting RhoA, it may modulate ARHGAP40 expression, as RhoA is a key player in the Rho GTPase signaling network that ARHGAP40 is involved in regulating. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective Cdc42 inhibitor. By inhibiting Cdc42, it may indirectly affect ARHGAP40 expression, given the interconnected nature of the Rho GTPase family in cellular signaling pathways. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
CASIN is a small molecule inhibitor of Cdc42. By blocking Cdc42 activity, it may influence ARHGAP40 expression, given the involvement of Cdc42 in the intricate regulation of Rho GTPase signaling pathways. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
EHT 1864 is a Rac1 inhibitor. By selectively inhibiting Rac1, it may impact ARHGAP40 expression, as Rac1 is a member of the Rho GTPase family involved in signaling pathways regulated by ARHGAP40. | ||||||
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone | sc-501166 | 5 mg | $540.00 | |||
Ipatasertib inhibits Akt, a downstream effector of the PI3K/Akt pathway. As ARHGAP40 expression may be influenced by PI3K/Akt signaling, Ipatasertib could indirectly affect ARHGAP40 expression. | ||||||